Ticker > Company >

Suven Life Sciences share price

Suven Life Sciences Ltd.

NSE: SUVEN BSE: 530239 SECTOR: Pharmaceuticals & Drugs  83k   139   25

134.72
-7.08 (-4.99%)
NSE: 20 Dec 04:02 PM

Price Summary

Today's High

₹ 144.6

Today's Low

₹ 133.35

52 Week High

₹ 169.3

52 Week Low

₹ 79.3

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyPoor
The company seems highly inefficient in case of asset management.
FinancialsWeak
Watch out! The company might not be able to sustain any adverse condition.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

2937.89 Cr.

Enterprise Value

2784.44 Cr.

No. of Shares

21.81 Cr.

P/E

0

P/B

3.55

Face Value

₹ 1

Div. Yield

0 %

Book Value (TTM)

₹  37.93

CASH

153.45 Cr.

DEBT

0 Cr.

Promoter Holding

70.27 %

EPS (TTM)

₹  -1.22

Sales Growth

-13.64%

ROE

-0.94 %

ROCE

-1.03%

Profit Growth

60.21 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year-13.64%
3 Year-4.63%
5 Year-47.23%

Profit Growth

1 Year60.21%
3 Year18.07%
5 Year-172.79%

ROE%

1 Year-0.94%
3 Year-4.2%
5 Year-4.42%

ROCE %

1 Year-1.03%
3 Year-4.03%
5 Year-5.06%

Debt/Equity

0

Price to Cash Flow

-142.87

Interest Cover Ratio

-36.4665

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Sep 2024 70.27 0.00
Jun 2024 70.27 0.00
Mar 2024 69.57 0.00
Dec 2023 69.57 0.00
Sep 2023 69.57 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company is virtually debt free.
  • The company has an efficient Cash Conversion Cycle of 54.7895 days.
  • Company has a healthy liquidity position with current ratio of 51.6972.
  • The company has a high promoter holding of 70.27%.

 Limitations

  • The company has shown a poor revenue growth of -4.62616530476045% for the Past 3 years.
  • Company has a poor ROE of -4.1980372724795% over the past 3 years.
  • Company has a poor ROCE of -4.03235014399487% over the past 3 years
  • Company has negative cash flow from operations of -20.563.
  • The company has a low EBITDA margin of -249.395109788504% over the past 5 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024
Net Sales 3.06 2.45 2.39 1.01 2.57
Total Expenditure 11.14 11.65 9.26 11.09 16.21
Operating Profit -8.08 -9.2 -6.87 -10.09 -13.64
Other Income 5.14 6.07 4.28 3.93 4.04
Interest 0.04 0.04 0.03 0.02 0.02
Depreciation 1.73 1.6 1.51 1.49 1.46
Exceptional Items 7.46 0 0 0 0
Profit Before Tax 2.76 -4.77 -4.13 -7.67 -11.07
Tax 0 0 -1 0 0
Profit After Tax 2.76 -4.77 -3.13 -7.67 -11.07
Adjusted EPS (Rs) 0.13 -0.22 -0.14 -0.35 -0.51

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 14.41 13.48 11.84 13.54 11.69
Total Expenditure 49.68 43.93 48.37 41.18 42.55
Operating Profit -35.26 -30.45 -36.53 -27.64 -30.85
Other Income 14.04 7.75 1.6 8.45 21.13
Interest 0.54 0.91 0.64 0.4 0.24
Depreciation 4.17 4.35 4.39 6.54 6.5
Exceptional Items 0 0 3.72 6 7.46
Profit Before Tax -25.94 -27.95 -36.25 -20.13 -9.01
Tax -12.18 -5.32 0 0 -1
Net Profit -13.75 -22.63 -36.25 -20.13 -8.01
Adjusted EPS (Rs.) -1 -1.64 -2.3 -0.92 -0.37

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 12.73 12.73 14.54 21.81 21.81
Total Reserves 374.95 388.93 461.44 831.64 823.57
Borrowings 1.08 0.39 0 0 0
Other N/C liabilities 10.99 4.11 3.57 2.46 1.35
Current liabilities 103.53 103.13 100.7 98.43 4.76
Total Liabilities 503.28 509.28 580.25 954.34 851.48
Assets
Net Block 24.69 20.96 37.56 37.21 28.21
Capital WIP 0 4.77 3.55 0 0
Intangible WIP 0 0 0 0 0
Investments 241.81 295.03 380.69 481.86 577.11
Loans & Advances 91.25 0 0.33 0.11 0.02
Other N/C Assets 0 0 0 100 0
Current Assets 145.52 188.52 158.12 335.16 246.14
Total Assets 503.28 509.28 580.25 954.34 851.48
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations -25.94 -27.96 -36.25 -20.13 -9.01
Adjustment -9.26 -2.7 -1.09 -8.09 -22.46
Changes in Assets & Liabilities -7.17 -4.88 1.24 6.4 4.73
Tax Paid -2.78 -1.15 -0.52 -1.1 6.18
Operating Cash Flow -45.15 -36.68 -36.62 -22.92 -20.56
Investing Cash Flow 42.03 2.41 -107.46 -348.82 -0.68
Financing Cash Flow 3.81 34.86 145.69 395.54 -1.05
Net Cash Flow 0.69 0.58 1.61 23.79 -22.3

Corporate Actions

Investors Details

PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
promoters 69.57 69.57 69.57 70.27 70.27
jasti property and equity... 69.56 69.56 69.56 69.56 69.56
sudharani jasti - - - 0.70 0.70
PARTICULARS Sep 2023% Dec 2023% Mar 2024% Jun 2024% Sep 2024%
investors 30.43 30.43 30.43 29.73 29.73
investor education and pr... 0.11 - - - 0.12
quant mutual fund - quant... - - 1.05 1.05 1.05
rambabu chirumamilla 1.38 1.38 1.38 1.38 1.38
investor education and pr... - 0.11 0.12 0.12 -

Ratings & Research Reports

Company Presentations

Company News

Suven Life Sciences informs about newspaper publication 3 Dec, 4:24 PM Suven Life Sciences - Quaterly Results 29 Oct, 12:51 PM Suven Life Sciences - Quaterly Results 29 Oct, 12:51 PM Suven Life Sciences - Quaterly Results 29 Oct, 12:51 PM Suven Life Sciences informs about certificate 7 Oct, 5:19 PM Suven Life Sciences informs about newspaper advertisement 6 Aug, 5:15 PM Suven Life Sciences - Quaterly Results 5 Aug, 1:12 PM Suven Life Sciences - Quaterly Results 5 Aug, 1:12 PM Suven Life Sciences - Quaterly Results 5 Aug, 1:12 PM Suven Pharmaceuticals informs about appointment of statutory auditors 13 Jul, 11:09 AM Suven Life Sciences informs about AGM notice 4 Jul, 5:22 PM Suven Life Sciences - Quaterly Results 6 May, 6:45 PM Suven Life Sciences - Quaterly Results 6 May, 6:45 PM Suven Pharmaceuticals to merge Cohance with itself 1 Mar, 11:30 AM Suven Life Sciences - Quaterly Results 30 Jan, 12:57 PM Suven Life Sciences - Quaterly Results 30 Jan, 12:57 PM Suven Life Sciences - Quaterly Results 30 Jan, 12:57 PM Suven Pharmaceuticals informs about board meeting 29 Jan, 5:23 PM Suven Pharmaceuticals informs about BRSR 23 Nov, 4:15 PM Suven Life Sciences - Quaterly Results 4 Nov, 12:41 PM Suven Life Sciences - Quaterly Results 4 Nov, 12:41 PM Suven Life Sciences - Quaterly Results 4 Nov, 12:41 PM Suven Pharmaceuticals informs about disclosure 26 Sep, 5:07 PM Suven Life Sciences informs about loss of share certificate 16 Sep, 3:58 PM CCEA approves foreign investment of up to Rs 9589 crore in Suven Pharmaceuticals 14 Sep, 4:37 PM Suven Life Sciences informs about monitoring agency report 9 Aug, 4:34 PM Suven Life Sciences - Quaterly Results 8 Aug, 1:02 PM Suven Life Sciences - Quaterly Results 8 Aug, 1:02 PM Suven Life Sciences - Quaterly Results 8 Aug, 1:02 PM Suven Life Sciences informs about newspaper publication 10 May, 1:09 PM Suven Life Sciences - Quaterly Results 9 May, 1:14 PM Suven Life Sciences - Quaterly Results 9 May, 1:14 PM Suven Life Sciences - Quaterly Results 9 May, 1:14 PM Suven Life Sciences informs about loss of share certificate 6 Mar, 5:00 PM Suven Life Sciences informs about monitoring agency report 9 Feb, 4:55 PM Suven Life Sciences informs about disclosure 2 Feb, 4:41 PM Suven Life Sciences - Quaterly Results 2 Feb, 1:46 PM Suven Life Sciences - Quaterly Results 2 Feb, 1:46 PM Suven Life Sciences - Quaterly Results 2 Feb, 1:46 PM Suven Life Sciences informs about compliances-certificate 6 Jan, 1:01 PM Suven Life Sciences randomizes first patient in phase-3 global clinical trial of Masupirdine 17 Nov, 11:59 AM Suven Life Sciences - Quaterly Results 10 Nov, 5:14 PM Suven Life Sciences - Quaterly Results 10 Nov, 5:14 PM Suven Life Sciences informs about compliance certificate 12 Oct, 12:11 PM Suven Life Sciences informs about closure of trading window 30 Sep, 4:44 PM Suven Life Sciences - Quaterly Results 26 Jul, 1:26 PM Suven Life Sciences - Quaterly Results 26 Jul, 1:26 PM Suven Life Sciences - Quaterly Results 26 Jul, 1:26 PM Suven Life Sciences informs about AGM 11 Jul, 3:33 PM Suven Life Sciences gets nod to raise Rs 400 crore on rights basis 24 Jun, 2:21 PM

Suven Life Sciences Stock Price Analysis and Quick Research Report. Is Suven Life Sciences an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Suven Life Sciences and its performance over the period of time. Suven Life Sciences stock price today is Rs 134.72.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Suven Life Sciences cash from the operating activity was Rs -20.563 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Suven Life Sciences has a Debt to Equity ratio of 0 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Suven Life Sciences , the EPS growth was 60.2167 % which is good for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Suven Life Sciences has OPM of -263.874658981091 % which is a bad sign for profitability.
     
  • ROE: Suven Life Sciences have a poor ROE of -0.9428 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Suven Life Sciences is Rs 134.72. One can use valuation calculators of ticker to know if Suven Life Sciences share price is undervalued or overvalued.
Last Updated on:
Brief about Suven Life Sciences
X